US Drugs Vulnerable: Labels for Origin Demanded

US lawmakers are advocating for country-of-origin labeling on prescription drugs, emphasizing the health system's vulnerability to foreign manufacturing disruptions. Senator Rick Scott introduced the CLEAR LABELS Act, which would require prescription drugs sold in the US to disclose their manufacturing origins and those of their key ingredients.

This initiative stems from concerns that 91% of US prescriptions are generics, with almost 94% of their active pharmaceutical ingredients (APIs) sourced overseas, mainly from China and India. During the Covid-19 pandemic, India's temporary restrictions on pharmaceutical exports highlighted potential supply chain risks.

Experts and officials noted that advance notice for foreign plant inspections by US regulators is problematic, potentially masking unsanitary conditions. The lack of transparency leaves patients and healthcare providers uninformed about medicine origins, posing both public health and national security risks. India remains a critical, though complex, supplier of generic pharmaceuticals.

Witnesses supported greater transparency, suggesting QR codes on packaging for origin and quality data. They cautioned that origin alone isn't a quality proxy and urged stronger incentives for domestic manufacturing. Some research indicates patient preference for US or Canadian-made drugs when origin is disclosed.